Skip to main content
Top
Published in: Journal of Neural Transmission 1/2016

01-01-2016 | Neurology and Preclinical Neurological Studies - Review Article

Advanced stages of PD: interventional therapies and related patient-centered care

Authors: Rejko Krüger, Rüdiger Hilker, Christian Winkler, Michael Lorrain, Matthias Hahne, Christoph Redecker, Paul Lingor, Wolfgang H. Jost

Published in: Journal of Neural Transmission | Issue 1/2016

Login to get access

Abstract

During the last decades, symptomatic treatment of motor symptoms of Parkinson’s disease (PD) improved continuously and is reflected by long-range independency of the patient during the disease course. However, advanced stages of PD still represent an important challenge to patients, caregivers and treating physicians. In patients with advanced PD, interventional therapy strategies are increasingly applied. These device-related treatment strategies using pump-based continuous dopaminergic stimulation (CDS) or deep brain stimulation (DBS) opened new treatment options especially if motor complications predominate. Well-designed clinical studies on these interventional therapeutic approaches provided class 1 evidence for the efficacy of DBS and CDS in advanced PD and opened new perspectives for their use in earlier disease stages also. Therefore, careful selection of patients amenable to the (semi)invasive therapy options becomes more and more important and requires an interdisciplinary setting that accounts for (i) optimal patient information and awareness, (ii) selection of best individual treatment modality, (iii) training of relatives and caregivers, (iv) management of complications, and (v) follow-up care. Here, we address these topics by summarizing current state-of-the-art in patient selection, providing specificities of treatment options and troubleshooting, and defining steps towards an optimized patient-centered care. Interventional therapies pioneer in the area of individualized treatment approaches for PD, and may be complemented in the future by biomarker-based improved stratification and by closed-loop systems for adaptive therapeutic strategies. In the present review, we summarize the proceedings of an Expert Workshop on Parkinson’s disease held on November 22, 2014 in Frankfurt, Germany.
Literature
go back to reference Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurotherapeutics 9:859–867. doi:10.1586/ern.09.48 CrossRef Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurotherapeutics 9:859–867. doi:10.​1586/​ern.​09.​48 CrossRef
go back to reference Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, investigators Gs, coordinators (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 21(3):231–235. doi:10.1016/j.parkreldis.2014.12.012 PubMedCrossRef Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, investigators Gs, coordinators (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 21(3):231–235. doi:10.​1016/​j.​parkreldis.​2014.​12.​012 PubMedCrossRef
go back to reference Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–462. doi:10.1002/mds.25844 PubMedPubMedCentralCrossRef Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–462. doi:10.​1002/​mds.​25844 PubMedPubMedCentralCrossRef
go back to reference Borgemeester RWK, Drent M, Laar TV (2014) Long-term data on subcutaneous apomorphine in Parkinson’s disease patients; a retrospective analysis of a Dutch cohort of 139 patients [abstract]. Mov Disord 29(Suppl 1):351 Borgemeester RWK, Drent M, Laar TV (2014) Long-term data on subcutaneous apomorphine in Parkinson’s disease patients; a retrospective analysis of a Dutch cohort of 139 patients [abstract]. Mov Disord 29(Suppl 1):351
go back to reference Bredberg E, Nilsson D, Johansson K et al (1993) Intraduodenal infusion of a water-based levodopa dispersion for optimization of the therapeutic effect in severe parkinsons-disease. Eur J Clin Pharmacol 45:117–122PubMedCrossRef Bredberg E, Nilsson D, Johansson K et al (1993) Intraduodenal infusion of a water-based levodopa dispersion for optimization of the therapeutic effect in severe parkinsons-disease. Eur J Clin Pharmacol 45:117–122PubMedCrossRef
go back to reference Breit S, LeBas JF, Koudsie A, Schulz J, Benazzouz A, Pollak P, Benabid AL (2008) Pretargeting for the implantation of stimulation electrodes into the subthalamic nucleus: a comparative study of magnetic resonance imaging and ventriculography. Neurosurgery 62(Suppl 2):840–852. doi:10.1227/01.neu.0000316286.29995.4c PubMed Breit S, LeBas JF, Koudsie A, Schulz J, Benazzouz A, Pollak P, Benabid AL (2008) Pretargeting for the implantation of stimulation electrodes into the subthalamic nucleus: a comparative study of magnetic resonance imaging and ventriculography. Neurosurgery 62(Suppl 2):840–852. doi:10.​1227/​01.​neu.​0000316286.​29995.​4c PubMed
go back to reference Bronte-Stewart H, Barberini C, Koop MM, Hill BC, Henderson JM, Wingeier B (2009) The STN β-band profile in Parkinson’sdisease is stationary and shows prolonged attenuation after deep brain stimulation. Exp Neurol 215(1):20–28PubMedCrossRef Bronte-Stewart H, Barberini C, Koop MM, Hill BC, Henderson JM, Wingeier B (2009) The STN β-band profile in Parkinson’sdisease is stationary and shows prolonged attenuation after deep brain stimulation. Exp Neurol 215(1):20–28PubMedCrossRef
go back to reference Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64(5):573–576PubMedPubMedCentralCrossRef Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64(5):573–576PubMedPubMedCentralCrossRef
go back to reference Devos D, for the French DUODOPA Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000. doi:10.1002/mds.22450 CrossRef Devos D, for the French DUODOPA Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000. doi:10.​1002/​mds.​22450 CrossRef
go back to reference Dewey RB Jr (2004) Management of motor complications in Parkinson’s disease. Neurology 62(6 Suppl 4):S3–S7PubMedCrossRef Dewey RB Jr (2004) Management of motor complications in Parkinson’s disease. Neurology 62(6 Suppl 4):S3–S7PubMedCrossRef
go back to reference Fasano A, Herzog J, Seifert E et al (2011) Modulation of gait coordination by subthalamic stimulation improves freezing of gait. MovDisord 26:844–851 Fasano A, Herzog J, Seifert E et al (2011) Modulation of gait coordination by subthalamic stimulation improves freezing of gait. MovDisord 26:844–851
go back to reference Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2014) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. doi:10.1002/mds.26123 PubMedPubMedCentral Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2014) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. doi:10.​1002/​mds.​26123 PubMedPubMedCentral
go back to reference Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 362(22):2077–2091PubMedCrossRef Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 362(22):2077–2091PubMedCrossRef
go back to reference Gancher ST, Nutt JG, Woodward WR (1991) Absorption of apomorphine by various routes in parkinsonism. Mov Disord 6(3):212–216PubMedCrossRef Gancher ST, Nutt JG, Woodward WR (1991) Absorption of apomorphine by various routes in parkinsonism. Mov Disord 6(3):212–216PubMedCrossRef
go back to reference Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 20(5):523–539. doi:10.1002/mds.20464 PubMedCrossRef Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 20(5):523–539. doi:10.​1002/​mds.​20464 PubMedCrossRef
go back to reference Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, Pinsker MO, Herzog H, Volkmann J, Deuschl G, Fink GR (2008) Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation. Brain J Neurol 131(Pt 1):132–145. doi:10.1093/brain/awm254 Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, Pinsker MO, Herzog H, Volkmann J, Deuschl G, Fink GR (2008) Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation. Brain J Neurol 131(Pt 1):132–145. doi:10.​1093/​brain/​awm254
go back to reference Hilker R, Antonini A, Odin P (2011) What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 118:907–914PubMedCrossRef Hilker R, Antonini A, Odin P (2011) What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 118:907–914PubMedCrossRef
go back to reference Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474. doi:10.1002/mds.22596 PubMedCrossRef Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474. doi:10.​1002/​mds.​22596 PubMedCrossRef
go back to reference Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ et al (1993) Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 8:165–170. doi:10.1002/mds.870080208 PubMedCrossRef Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ et al (1993) Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 8:165–170. doi:10.​1002/​mds.​870080208 PubMedCrossRef
go back to reference Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20(2):151–157. doi:10.1002/mds.20276 PubMedCrossRef Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20(2):151–157. doi:10.​1002/​mds.​20276 PubMedCrossRef
go back to reference Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17(6):1235–1241. doi:10.1002/mds.10281 PubMedCrossRef Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17(6):1235–1241. doi:10.​1002/​mds.​10281 PubMedCrossRef
go back to reference Meier U, Diener HC (2007) Integrierte versorgung in der neurologie: integrierte versorgungskonzepte und kooperative versorgungsstrukturen. Georg Thieme Verlag, StuttgartCrossRef Meier U, Diener HC (2007) Integrierte versorgung in der neurologie: integrierte versorgungskonzepte und kooperative versorgungsstrukturen. Georg Thieme Verlag, StuttgartCrossRef
go back to reference Moro E, Volkmann J, Konig IR, Winkler S, Hiller A, Hassin-Baer S, Herzog J, Schnitzler A, Lohmann K, Pinsker MO, Voges J, Djarmatic A, Seibler P, Lozano AM, Rogaeva E, Lang AE, Deuschl G, Klein C (2008) Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 70(14):1186–1191. doi:10.1212/01.wnl.0000307748.11216.03 PubMedCrossRef Moro E, Volkmann J, Konig IR, Winkler S, Hiller A, Hassin-Baer S, Herzog J, Schnitzler A, Lohmann K, Pinsker MO, Voges J, Djarmatic A, Seibler P, Lozano AM, Rogaeva E, Lang AE, Deuschl G, Klein C (2008) Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 70(14):1186–1191. doi:10.​1212/​01.​wnl.​0000307748.​11216.​03 PubMedCrossRef
go back to reference Morrell M (2006) Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures? CurrOpinNeurol 19(2):164–168 Morrell M (2006) Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures? CurrOpinNeurol 19(2):164–168
go back to reference Naidu Y, Tluk S, Martin A, Jacobs S, Davidson C, Richards C, Martinez-Martin P, Chaudhuri KR (2009) Initiation of apomorphine infusion in advanced Parkinson’s disease and effect on non-motor symptoms compared to non-invasive strategies. Mov Disord 24(Suppl 1):S360 Naidu Y, Tluk S, Martin A, Jacobs S, Davidson C, Richards C, Martinez-Martin P, Chaudhuri KR (2009) Initiation of apomorphine infusion in advanced Parkinson’s disease and effect on non-motor symptoms compared to non-invasive strategies. Mov Disord 24(Suppl 1):S360
go back to reference Odekerken VJ, van Laar T, Staal MJ et al (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12(1):37–44PubMedCrossRef Odekerken VJ, van Laar T, Staal MJ et al (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12(1):37–44PubMedCrossRef
go back to reference Okun MS, Tagliati M, Pourfar M et al (2005) Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 62:1250–1255PubMedCrossRef Okun MS, Tagliati M, Pourfar M et al (2005) Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 62:1250–1255PubMedCrossRef
go back to reference Okun MS, Gallo BV, Mandybur G et al (2012) Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurol 11:140–149PubMedCrossRef Okun MS, Gallo BV, Mandybur G et al (2012) Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurol 11:140–149PubMedCrossRef
go back to reference Olanow CW, Kieburtz K, Odin P, Espay AJ (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. doi:10.1016/S1474-4422(13)70293-X PubMedCentral Olanow CW, Kieburtz K, Odin P, Espay AJ (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. doi:10.​1016/​S1474-4422(13)70293-X PubMedCentral
go back to reference Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L (1993) Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patients. Adv Neurol 60:656–659PubMed Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L (1993) Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patients. Adv Neurol 60:656–659PubMed
go back to reference Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL (1989) Subcutaneous apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52(4):544PubMedPubMedCentralCrossRef Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL (1989) Subcutaneous apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52(4):544PubMedPubMedCentralCrossRef
go back to reference Russmann H, Ghika J, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR et al (2004) Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 63:1952–1954PubMedCrossRef Russmann H, Ghika J, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR et al (2004) Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 63:1952–1954PubMedCrossRef
go back to reference Schupbach M, Lohmann E, Anheim M, Lesage S, Czernecki V, Yaici S, Worbe Y, Charles P, Welter ML, Pollak P, Durr A, Agid Y, Brice A (2007) Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Mov Disord 22(1):119–122. doi:10.1002/mds.21178 PubMedCrossRef Schupbach M, Lohmann E, Anheim M, Lesage S, Czernecki V, Yaici S, Worbe Y, Charles P, Welter ML, Pollak P, Durr A, Agid Y, Brice A (2007) Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Mov Disord 22(1):119–122. doi:10.​1002/​mds.​21178 PubMedCrossRef
go back to reference Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144–1148PubMedCrossRef Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144–1148PubMedCrossRef
go back to reference Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1(8582):403–406PubMedCrossRef Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1(8582):403–406PubMedCrossRef
go back to reference Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol 22(1):93–94 Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol 22(1):93–94
go back to reference Sudmeyer M, Volkmann J, Wojtecki L, Deuschl G, Schnitzler A, Moller B (2012) Deep brain stimulation - expectations and doubts. A nationwide questionnaire study of patients with Parkinson’s disease and their family members. Der Nervenarzt 83(4):481–486. doi:10.1007/s00115-011-3400-x PubMedCrossRef Sudmeyer M, Volkmann J, Wojtecki L, Deuschl G, Schnitzler A, Moller B (2012) Deep brain stimulation - expectations and doubts. A nationwide questionnaire study of patients with Parkinson’s disease and their family members. Der Nervenarzt 83(4):481–486. doi:10.​1007/​s00115-011-3400-x PubMedCrossRef
go back to reference Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63–73PubMedPubMedCentralCrossRef Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63–73PubMedPubMedCentralCrossRef
go back to reference Weiss D, Walach M, Meisner C, Fritz M, Scholten M, Breit S, Plewnia C, Bender B, Gharabaghi A, Wachter T, Kruger R (2013) Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial. Brain J Neurol 136(Pt 7):2098–2108. doi:10.1093/brain/awt122 CrossRef Weiss D, Walach M, Meisner C, Fritz M, Scholten M, Breit S, Plewnia C, Bender B, Gharabaghi A, Wachter T, Kruger R (2013) Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial. Brain J Neurol 136(Pt 7):2098–2108. doi:10.​1093/​brain/​awt122 CrossRef
Metadata
Title
Advanced stages of PD: interventional therapies and related patient-centered care
Authors
Rejko Krüger
Rüdiger Hilker
Christian Winkler
Michael Lorrain
Matthias Hahne
Christoph Redecker
Paul Lingor
Wolfgang H. Jost
Publication date
01-01-2016
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 1/2016
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-015-1418-0

Other articles of this Issue 1/2016

Journal of Neural Transmission 1/2016 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

Parkinson’s disease between internal medicine and neurology

Neurology and Preclinical Neurological Studies - Review Article

Modern treatment in Parkinson’s disease, a personal approach

Editorial

Preface

Neurology and Preclinical Neurological Studies - Review Article

Therapy-resistant symptoms in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

Psychosis in Parkinson’s disease: identification, prevention and treatment